| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/19/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 05/11/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 03/22/2023 |
8-K
| Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard... |
| 02/28/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/28/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 02/22/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Veradigm Announces Two New Appointments to its Board Pharmaceutical executive Susan Rodriguez and digital health/pharma services entrepreneur Dr. Shih-Yin Ho join Board of Directors CHICAGO – FEBRUARY 22, 2023 – Susan Rodriguez and Shih-Yin Ho, MD have been named to the Board of Directors of Veradigm Inc. . With their combined experience in the pharmaceutical industry, digital health, and healthcare, together they bring a wealth of experience to Veradigm, to help build upon the company’s vision of transforming health, insightfully. Ms. Rodriguez joins the Veradigm Board with over 30 years of experience in the biopharmaceutical industry, in a broad range of executive leadership roles. She currently serves as Chief Commercial Officer at Ardelyx, Inc., where she has been responsible for leadi..." |
|
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 12.4% stake in Allscripts Healthcare Solutions Inc. |
| 01/26/2023 |
SC 13G/A
| BlackRock Inc. reports a 19.1% stake in ALLSCRIPTS HEALTHCARE SOLUTIONS INC |
| 01/20/2023 |
SC 13G/A
| BlackRock Inc. reports a 19.1% stake in ALLSCRIPTS HEALTHCARE SOLUTIONS INC |
| 01/11/2023 |
8-K
| Investor presentation |
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 09/28/2022 |
8-K
| Investor presentation |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/04/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 06/22/2022 |
8-K
| Quarterly results |
| 05/09/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/09/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/06/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/05/2022 |
8-K
| Quarterly results |
| 05/02/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 03/04/2022 |
8-K
| Quarterly results |
| 03/03/2022 |
8-K
| Quarterly results |
| 03/02/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/25/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/24/2022 |
8-K
| Quarterly results |
| 02/11/2022 |
5
| STEVENS DAVID D (Director) has filed a Form 5 on ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. |
| 02/11/2022 |
5
| Poulton Richard J. (President & CFO) has filed a Form 5 on ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. |
| 02/10/2022 |
SC 13G
| SHAPIRO CAPITAL MANAGEMENT LLC reports a 3% stake in ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. |
| 02/10/2022 |
SC 13G
| SHAPIRO CAPITAL MANAGEMENT LLC reports a 5.1% stake in ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. |
|